治疗性抗体药物开发中IgG亚型选择

治疗性抗体药物针对不同的适应证具有专一性和有效性。目前已上市的治疗性抗体药物多是以IgG为框架开发的，并且绝大部分属于IgG1亚型。在治疗性抗体药物的开发中，由于各亚型具有不同的结构与功能，影响其理化性质、生物活性和触发效应功能的能力等，为达到期望的治疗效果并且避免不良反应，应选择适宜的抗体亚型进行抗体设计。主要综述了影响IgG亚型选择的相关因素，以及IgG1、IgG2和IgG4亚型在治疗性抗体药物开发中的应用研究，以期为治疗性抗体药物研发提供新思路。

Subclasses Selection in Therapeutic Antibody Development

Therapeutic antibody drugs with specificity and efficiency have been developed for different indications.The therapeutic antibody drugs have frameworks from IgG, most of which belong to the IgG1 isotype. Due to various subclasses with different structure and function, affect the physical and chemical properties, biological activity and the ability to trigger effector function and so on, in the process of the research and development of therapeutic antibody drugs, it is important to choose the suitable antibody subclass in design to achieve the desired effect and reduce side effects. The curative related effect of choosing IgG subclass and the development of selecting of IgG subclass for the research and application were reviewed, in order to provide new ideas for therapeutic antibody drugs development.